| 4.14 0.04 (0.98%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.36  |
1-year : | 5.75 |
| Resists | First : | 4.59 |
Second : | 4.92 |
| Pivot price | 4.5 |
|||
| Supports | First : | 4.05 |
Second : | 3.36 |
| MAs | MA(5) : | 4.27 |
MA(20) : | 4.51 |
| MA(100) : | 4.25  |
MA(250) : | 3.97 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 11.9 |
D(3) : | 21.8 |
| RSI | RSI(14): 42.8 |
|||
| 52-week | High : | 9.68 | Low : | 0.75 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MRKR ] has closed above bottom band by 10.1%. Bollinger Bands are 30.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.26 - 4.29 | 4.29 - 4.31 |
| Low: | 3.99 - 4.02 | 4.02 - 4.05 |
| Close: | 4.09 - 4.14 | 4.14 - 4.18 |
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
Mon, 08 Apr 2024
Marker Therapeutics' MT-601 Shows Promising Results - TipRanks.com - TipRanks
Fri, 29 Mar 2024
MRKR Stock Quote Price and Forecast - CNN
Wed, 27 Mar 2024
Marker Therapeutics Full Year 2023 Earnings: US$1.59 loss per share (vs US$3.58 loss in FY 2022) - Simply Wall St
Tue, 26 Mar 2024
Marker Therapeutics Inc (MRKR) Stock Gains 2.73% This Week; Should You Buy? - InvestorsObserver
Mon, 22 Jan 2024
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International ... - Yahoo Finance
Mon, 08 Jan 2024
Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 12.1 (%) |
| Held by Institutions | 22.9 (%) |
| Shares Short | 108 (K) |
| Shares Short P.Month | 161 (K) |
| EPS | -1.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.58 |
| Profit Margin | -248.8 % |
| Operating Margin | -278.1 % |
| Return on Assets (ttm) | -35.4 % |
| Return on Equity (ttm) | -83.5 % |
| Qtrly Rev. Growth | 39.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.37 |
| EBITDA (p.s.) | -1.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -2.61 |
| PEG Ratio | 0 |
| Price to Book value | 2.62 |
| Price to Sales | 11.13 |
| Price to Cash Flow | -2.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|